The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make “go, no-go” decisions to proceed to later phase trials. Clin Cancer Res; 23(5); 1–3. ©2016 AACR.
See related article by Calvo et al., p. 1177
- Received October 6, 2016.
- Accepted October 11, 2016.
- ©2016 American Association for Cancer Research.